A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma.

Ota, Hiroaki; Munechika, Miyuki; Tobino, Kazunori; Uchida, Kazuki; Muarakami, Yosuke

Ota, Hiroaki; Munechika, Miyuki; Tobino, Kazunori; Uchida, Kazuki; Muarakami, Yosuke.

Afiliación

Ota H; Respiratory Medicine, Iizuka Hospital, Iizuka, JPN.
Munechika M; Respiratory Medicine, Iizuka Hospital, Iizuka, JPN.
Tobino K; Respiratory Medicine, Iizuka Hospital, Iizuka, JPN.
Uchida K; Respiratory Medicine, Iizuka Hospital, Iizuka, JPN.
Muarakami Y; Respiratory Medicine, Iizuka Hospital, Iizuka, JPN.

Cureus ; 16(4): e58253, 2024 Apr.

Article en En | MEDLINE | ID: mdl-38745801

ABSTRACT

ABSTRACT

Immune checkpoint inhibitors (ICIs) are used to treat a variety of tumors. Despite their broad beneficial effects, these inhibitors can cause immune-related adverse events (irAEs) and even death. Hemophagocytic lymphohistiocytosis (HLH) and meningitis, although infrequent, can be aggressive and life-threatening due to excessive immune activation. Herein, we report a case of an 80-year-old man who developed HLH after receiving atezolizumab monotherapy as a second-line treatment for lung adenocarcinoma. He was treated for HLH with oral prednisolone (PSL), but further ataxia and dysuria developed, and a lumbar puncture diagnosed meningitis. Both HLH and meningitis improved with continued oral PSL treatment. This is the first case of atezolizumab-induced HLH with meningitis and highlights the importance of early diagnosis and treatment for rare irAE.

Palabras clave

atezolizumab; hlh; ici; irae; meningitis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google